Evogene Reports First Quarter 2026 Financial Results
Evogene reported Q1 2026 revenue of $0.3 million, a significant decline from $2.3 million in the prior year, driven by the wind-down of non-core subsidiaries like Casterra. The company posted a net loss of $5.9 million, widening from $3.0 million year-over-year, largely due to decreased revenues and increased financing expenses related to warrant revaluations.
Key figures
- Revenue
- 334000
- Revenue Yoy
- -86%
- Net loss
- 5896000
- Operating loss
- 3150000
- R and d expense
- 1839000
- Warrant liability
- 1721000
- Shares outstanding
- 10412764
- Financing expense net
- 2713000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.